Functional Impairment and Changes in Depression Subtypes for Women in STAR*D: A Latent Transition Analysis.
To characterize the association between functional impairment and major depression subtypes at baseline and to characterize changes in subtypes by functional impairment level in women receiving citalopram in level 1 of the Sequenced Treatment Alternatives to Relieve Depression trial.



Women who completed baseline and week 12 study visits were included. Items from the self-reported Quick Inventory of Depressive Symptomatology were used to define the latent depression subtypes. The Work and Social Adjustment Scale was used to classify baseline functional impairment. A latent transition analysis model provided estimates of the prevalence of subtype membership and transition probabilities by functional impairment level.



Of the 755 women included, 69% had major functional impairment at baseline. Regardless of functional impairment level, the subtypes were differentiated by depression severity, appetite changes, psychomotor disturbances, and insomnia. Sixty-seven percent of women with normal/significant functional impairment and 60% of women with major impairment were likely to transition to a symptom resolution subtype at week 12. Women with baseline major impairment who were in the severe with psychomotor agitation subtype at the beginning of the study were least likely to transition to the symptom resolution subtype (4% chance).



Functional impairment level was related to both the baseline depression subtype and the likelihood of moving to a different subtype. These results underscore the need to incorporate not only depression symptoms but also functioning in the assessment and treatment of depression.
1 Department of Quantitative Health Sciences, University of Massachusetts Medical School , Worcester, Massachusetts.
Christine M
CM
Ulbricht
2 Center for Psychopharmacologic Research and Treatment, Department of Psychiatry, University of Massachusetts Medical School , Worcester, Massachusetts.|3 UMass Memorial Healthcare, Worcester, Massachusetts.
Anthony J
AJ
Rothschild
1 Department of Quantitative Health Sciences, University of Massachusetts Medical School , Worcester, Massachusetts.
Kate L
KL
Lapane
D000328:Adult; D000368:Aged; D018687:Antidepressive Agents, Second-Generation / Q000627:therapeutic use*; D001008:Anxiety Disorders / Q000453:epidemiology / Q000523:psychology; D015283:Citalopram / Q000627:therapeutic use*; D003863:Depression / Q000145:classification* / Q000175:diagnosis / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D017063:Outcome Assessment, Health Care / Q000379:methods; D010555:Personality Inventory; D011569:Psychiatric Status Rating Scales; D011788:Quality of Life / Q000523:psychology*; D057566:Self Report; D012720:Severity of Illness Index; D007319:Sleep Initiation and Maintenance Disorders / Q000150:complications* / Q000175:diagnosis / Q000453:epidemiology; D011795:Surveys and Questionnaires
D018687:Antidepressive Agents, Second-Generation; D015283:Citalopram